Multivariable-Adjusted HRs and 95% CIs

	N	HR (95% CI)
Nonfatal	1398	
hsCRP		0.99 (0.92, 1.06)
Fibrinogen		1.08 (1.00, 1.16)
GlycA		0.99 (0.93, 1.06)
sICAM-1		0.94 (0.89, 1.00)
Lymph Nodes		
No Metastasis	1040	
hsCRP		1.01 (0.93, 1.10)
Fibrinogen		1.15 (1.06, 1.26)
GlycA		0.97 (0.90, 1.06)
sICAM-1		0.93 (0.87, 1.00)
Metastasis	380	
hsCRP		0.99 (0.87, 1.14)
Fibrinogen		0.98 (0.93, 1.04)
GlycA		0.99 (0.87, 1.13)
sICAM-1		0.92 (0.83, 1.03)
Hormone Receptor		
ER+/PR+	1066	
hsCRP		0.96 (0.88, 1.04)
Fibrinogen		1.10 (1.01, 1.20)
GlycA		1.00 (0.92, 1.08)
sICAM-1		0.97 (0.91, 1.04)
ER+/PR-	165	
hsCRP		0.99 (0.80, 1.21)
Fibrinogen		1.01 (0.84, 1.21)
GlycA		0.98 (0.80, 1.19)
sICAM-1		0.84 (0.71, 0.99)
ER-/PR-	189	
hsCRP		1.17 (0.96, 1.42)
Fibrinogen		0.98 (0.88, 1.09)
GlycA		0.91 (0.76, 1.09)
sICAM-1		0.84 (0.71, 0.98)
Differentiation	368	
Well		
hsCRP		0.92 (0.80, 1.05)
Fibrinogen		1.34 (1.16, 1.55)
GlycA		0.93 (0.81, 1.06)
sICAM-1		0.96 (0.86, 1.08)
Moderate	672	
hsCRP		1.06 (0.95, 1.17)
Fibrinogen		0.98 (0.93, 1.04)
GlycA		0.95 (0.86, 1.04)
sICAM-1		0.92 (0.84, 1.00)
Poor	323	
hsCRP		1.02 (0.88, 1.19)
Fibrinogen		1.03 (0.89, 1.19)
GlycA		1.04 (0.90, 1.21)
sICAM-1		0.92 (0.82, 1.04)
Tumor Size		
≤2 cm	1104	
hsCRP		0.98 (0.91, 1.07)
Fibrinogen		1.09 (1.00, 1.18)
GlycA		0.99 (0.92, 1.08)
sICAM-1		0.93 (0.87, 0.99)
>2 cm	334	
hsCRP		1.04 (0.90, 1.21)
Fibrinogen		1.05 (0.90, 1.22)
GlycA		0.96 (0.84, 1.11)
sICAM-1		0.95 (0.84, 1.07)
Follow-up Years		
1-9	818	
hsCRP		1.01 (0.92, 1.11)
Fibrinogen		1.11 (1.00, 1.22)
GlycA		0.93 (0.85, 1.01)
sICAM-1		0.90 (0.83, 0.97)
≥10	679	
hsCRP		1.00 (0.90, 1.11)
Fibrinogen		1.02 (0.92, 1.12)
GlycA		0.99 (0.89, 1.09)
sICAM-1		0.98 (0.90, 1.07)

Lower Risk   Higher Risk

0.85   1.35

Web Figure 1. Multivariable Cox proportional hazards models for biomarkers of inflammation and risk of incident breast cancer by breast cancer subtypes in the Women's Health Study (1993-2013). Point estimates and bars represent hazard ratios and 95% confidence intervals. Abbreviations: HR=hazard ratio, CI=confidence interval, hsCRP=high sensitivity C-reactive protein, GlycA=N-linked glycoproteins, sICAM-1=soluble intercellular adhesion molecule-1, ER=estrogen receptor, PR=progesterone receptor. Estimates are from multivariable models adjusted for age, treatment randomization, family history of breast cancer in a relative <60 years of age (yes/no), personal history of benign breast disease (yes/no), Caucasian race/ethnicity (yes/no), menopausal status (premenopausal, postmenopausal, unsure), hormone therapy use (never, past, current), type of most recent hormone therapy use among ever users (estrogen alone, estrogen plus progestogen, other), age at menarche (≤11 years, 12, 13, ≥14), parity (nulliparous, 1-2 pregnancies ≥6 months, 3-4, ≥5), age at first birth (nulliparous, <30 years, ≥30), oral contraceptive use (never/ever), mammography screening (yes/no), Alternative Healthy Eating Index 2010 (quartiles), physical activity (metabolic equivalent task-hours [MET-hours]/week, quartiles), usual alcohol intake (rarely/never, 1-3 drinks/month, 1-6 drinks/week, ≥1 drink/day), smoking status (never, past, current), body mass index (<18.5 kg/m^2, 18.5-19.9, 20.0-22.4, 22.5-24.9, 25.0-27.4, 27.5-29.9, 30.0-34.9, ≥35.0), and the other biomarkers presented in the figure. The standard deviations for log-transformed concentrations of hsCRP = 1.20, fibrinogen = 0.25, GlycA = 0.18, and sICAM-1 = 0.22.